Earnings Releases·Nov 5, 2026, 4:05 PM ET

Celcuity Inc. — Third Quarter 2026 Earnings Summary

Net loss widened to $73.3 million ($1.33/share) from $43.8 million ($0.92/share) in the prior year period, driven by a 80% increase in total operating expenses to $77.3 million, primarily due to a $50 million Pfizer payment triggered by FDA approval.
REVTORPYK commercial launch commenced on September 30, 2026, with no revenue recognized in the quarter; the company secured NCCN Category 1 status, achieved 91% U.S. insurance coverage, and engaged over 3,400 sites.
Balance sheet deterioration occurred with stockholders' equity shifting to a deficit of $(74.0) million from $100.6 million, while convertible notes and total liabilities rose to $754.0 million and $800.9 million, respectively.
Management projects current cash reserves of $642.7 million will fund operations through 2029, with Phase 3 VIKTORIA-1 data submission expected late 2026 or early 2027 and a Phase 2 prostate cancer study scheduled for H1 2027.